Cat. No. 1098
Chemical Name: 2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2
Biological ActivityAntiallergic via inhibition of chemical mediator release from mast cells. Shown to be an effective inhibitor of angiogenesis. Demonstrated to antagonize the effects of angiotensin II on human arteries, possibly by an interaction at the level of the AT1 receptor. Inhibits TRPV2-mediated responses; binds to Aβ40 monomers and increases Aβ40 fibrillation.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Connors et al (2013) Tranilast binds to Aβ monomers and promotes Aβ fibrillation. Biochemistry. PMID: 23679559.
Hisanaga et al (2009) Regulation of calcium-permeable TRPV2 channel by insulin in pancreatic beta-cells. Diabetes. 58 174. PMID: 18984736.
Jin et al (1998) Tranilast, an anti-allergic drug, possesses antagonistic potency to angiotensin II. Eur.J.Pharmacol. 361 199. PMID: 9865509.
Isaji et al (1997) Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo. Br.J.Pharmacol. 122 1061. PMID: 9401770.
Hishikawa et al (1996) Tranilast restores cytokine-induced nitric oxide production against platelet derived growth factor in vascular smooth muscle cells. J.Cardiovasc.Pharmacol. 28 200. PMID: 8856474.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Tranilast from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Tranilast, supplier, Anti-allergic, inhibits, inhibitors, release, mast, cells, Antiangiogenics, TRPV2, amyloid, beta, AB, monomers, alzheimers, amyloidbeta, amyloidb, amyloidβ, Tocris Bioscience, Antiangiogenic products